Although we found a similar correlation between clinical outcome and course of BACE‐1 concentrations after 6 months of treatment as aforementioned for alpha‐synuclein, our overall data regarding BACE‐1 provide no convincing evidence that this protein might reflect pathogenic mechanisms important for SMA. This evidence concerns the gene BACE1 and proximal spinal muscular atrophy.